Embremma Injection is used in the treatment of breast cancer. It is used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other anticancer medicines after the cancer has spread.

Embremma Injection

Uses of Embremma Injection

Metastatic breast cancer

Benefits of Embremma Injection

In Metastatic breast cancer

Embremma Injection helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. This medicine is used when other medicines have not shown significant improvement and the cancer has spread to other parts as well. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Embremma Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.

Side effects of Embremma Injection

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Embremma

Anemia (low number of red blood cells)
Weakness
Hair loss
Nausea
Constipation
Decreased white blood cell count
Fatigue
Peripheral neuropathy (tingling and numbness of feet and hand)

How to use Embremma Injection

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How Embremma Injection works

Embremma Injection is an anticancer medication. It works by interfering with the microtubule structures which help the cancer cells to divide and multiply. This blocks the growth cycle (cell cycle) of cancer cells and eventually kills them.

Safety advice

Alcohol

CONSULT YOUR DOCTOR

It is not known whether it is safe to consume alcohol with Embremma Injection. Please consult your doctor.

Pregnancy

CONSULT YOUR DOCTOR

Embremma Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding

UNSAFE

Embremma Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.

Driving

UNSAFE

Embremma Injection may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.

Kidney

CAUTION

Embremma Injection should be used with caution in patients with kidney disease. Dose adjustment of Embremma Injection may be needed. Please consult your doctor.

Liver

CAUTION

Embremma Injection should be used with caution in patients with liver disease. Dose adjustment of Embremma Injection may be needed. Please consult your doctor.

All substitutes

For informational purposes only. Consult a doctor before taking any medicines.

Embremma Injection

₹19500.0/Injection

Evaira Injection

Zydus Cadila

₹20995/injection

8% costlier

Teceris Injection

Mylan Pharmaceuticals Pvt Ltd - A Viatris Company

₹31880/injection

63% costlier

Quick tips

Embremma Injection helps treat breast cancer that has spread to other areas of the body.
It is given by an injection into a vein (intravenously).
It may cause dizziness and tiredness. Do not drive or do anything requiring concentration until you know how it affects you.
Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for three months after you stop taking it.
Your doctor may get regular blood tests done to monitor your blood cells and electrolyte levels during treatment with this medicine.
Inform your doctor immediately if you notice any signs of infection such as fever, sore throat, rash or severe diarrhea while taking this medicine.
It may cause numbness, tingling or pricking sensations in your hands and feet. Inform your doctor if this bothers you.

Fact Box

Chemical Class

Synthetic analogue of halichondrin B

Habit Forming

Therapeutic Class

ANTI NEOPLASTICS

Action Class

Antimicrotubule agents- Non Taxanes

Patient concerns

BREAST CANCER , PET REPORT SAYS INFECTION IN SKELETON.

Dr. Sanjay Singh Rai

Medical Oncology and Hematology

Metastatic breast cancer, send me previous treatment details

Breast cancer With lympnode and few skeletal metastatic

Dr. Vijay Sharnangat

Medical Oncology and Hematology

What a bout ER PR AND HER2

FAQs

Is hair loss caused by Embremma Injection irreversible?

Hair loss is a common side effect of Embremma Injection. It could be reversible but the severity of hair loss varies from person to person. Consult your doctor if you have any concerns regarding hair loss.

How long can I stay on Embremma Injection?

Embremma Injection is usually given on Days 1 and 8 of each recommended 21-day cycle. The duration of treatment varies from person to person. The number of cycles required for effective treatment will be decided by your doctor. Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. If required, the doctor may also decide to reduce the dose you are given.

How is Embremma Injection Mesylate administered?

Embremma Injection will be given to you by a doctor or healthcare professional as an injection into a vein, over a period of 2 to 5 minutes. The dose required will be decided based on your body surface area (expressed in square metres, or m2) which is calculated from your weight and height. The doctor may adjust the usual dose based on your blood test results or other factors. To ensure that the whole dose of Embremma Injection is given, it is recommended that a saline solution is flushed into the vein after Embremma Injection is given.

What are the serious side effects of Embremma Injection?

Embremma Injection can cause serious side effects which include low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. It can also cause numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with Embremma Injection and sometimes can be severe. It can cause harm to the baby when administered to a pregnant woman.

When can I plan a pregnancy if I am using Embremma Injection?

Women of childbearing age should use effective contraception during and up to 3 months after treatment with Embremma Injection.It may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after carefully considering all the risk to you and the baby.

What precautions should be followed while handling Embremma Injection?

Embremma Injection should be handled carefully. Avoid any contact with skin, eyes, mouth and insides of nose. It is recommended to use gloves, goggles, and protective clothing while handling the medicine. If the skin comes into contact with the solution, it should be washed immediately and thoroughly with soap and water. Similarly, if your eyes, mouth or nose come in contact with Embremma Injection, flush the area thoroughly with water. Pregnant staff should not handle Embremma Injection.

In which solution should Embremma Injection injection be diluted?

Embremma Injection may be diluted in up to 100 ml of sodium chloride 9 mg/ml (0.9%) solution and not in 5% dextrose. It should be given under the supervision of a physician experienced in giving cancer chemotherapy and should be administered by a health care professional only.

Show less

Want to share the information?

Disclaimer:

Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

References

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 489.
Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
Eribulin Mesylate. Frankfurt am Main Germany: Eisai GmbH; 17 Mar. 2011 [revised Jan. 2019]. [Accessed 27 Mar. 2019] (online) Available from:
Cancer Research Uk. Eribulin Mesylate. [Accessed 27 Mar. 2019] (online) Available from:

Marketer details

Name: Emcure Pharmaceuticals Ltd

Address: 255/2, Hinjawadi, Pune - 411057, India

Country of origin: India

MRP

₹19500

Inclusive of all taxes

2.0 ml in 1 vial

SOLD OUT

Notify me

We provide you with authentic, trustworthy and relevant information

Have issue with the content?